In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Repligen Corp (RGEN), with a price target of $60. The company’s shares closed on Friday at $66.22, close to its 52-week high of $68.12.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -8.0% and a 31.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Repligen Corp with a $65 average price target.
See today’s analyst top recommended stocks >>
Repligen Corp’s market cap is currently $2.9B and has a P/E ratio of 127.35. The company has a Price to Book ratio of 4.84.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Nicolas Barthelemy, a Director at RGEN sold 6,580 shares for a total of $358,149.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Repligen Corp. engages in the provision of bioprocessing technology and solutions. It operates through the following geographical segments: United States; Sweden; United Kingdom; and Other. It also serve through the following product lines: Protein; Filtration; Chromatography; and Other.
